News coverage about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aptose Biosciences earned a news impact score of 0.11 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.2699178678249 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of brokerages have recently issued reports on APTO. Roth Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Aptose Biosciences in a report on Monday, October 23rd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Aptose Biosciences in a report on Wednesday, December 13th. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 25th. ValuEngine raised Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 31st. Finally, Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.00.
Aptose Biosciences (APTO) traded up $0.14 during mid-day trading on Friday, reaching $2.48. The company’s stock had a trading volume of 414,964 shares, compared to its average volume of 685,352. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $2.58. The company has a market capitalization of $65.40, a P/E ratio of -4.13 and a beta of 2.18.
ILLEGAL ACTIVITY NOTICE: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/01/14/aptose-biosciences-apto-earning-somewhat-favorable-press-coverage-analysis-finds.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.